Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCapital LeasesCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsOperating LeasesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Denali Therapeutics (DNLI) Current Deferred Revenue (2018 - 2023)

Denali Therapeutics (DNLI) has disclosed Current Deferred Revenue for 6 consecutive years, with $1.3 million as the latest value for Q2 2023.

  • On a quarterly basis, Current Deferred Revenue changed N/A to $1.3 million in Q2 2023 year-over-year; TTM through Jun 2023 was $1.3 million, a N/A change, with the full-year FY2022 number at $290.1 million, up 939.06% from a year prior.
  • Current Deferred Revenue was $1.3 million for Q2 2023 at Denali Therapeutics, down from $290.1 million in the prior quarter.
  • In the past five years, Current Deferred Revenue ranged from a high of $290.1 million in Q4 2022 to a low of $23000.0 in Q3 2022.
  • A 5-year average of $35.2 million and a median of $19.9 million in 2020 define the central range for Current Deferred Revenue.
  • Peak YoY movement for Current Deferred Revenue: skyrocketed 2548.51% in 2019, then tumbled 98.26% in 2022.
  • Denali Therapeutics' Current Deferred Revenue stood at $18.7 million in 2019, then increased by 6.27% to $19.9 million in 2020, then surged by 40.18% to $27.9 million in 2021, then soared by 939.06% to $290.1 million in 2022, then crashed by 99.55% to $1.3 million in 2023.
  • Per Business Quant, the three most recent readings for DNLI's Current Deferred Revenue are $1.3 million (Q2 2023), $290.1 million (Q4 2022), and $23000.0 (Q3 2022).